文献速递妇科肿瘤

铂耐药卵巢癌化疗患者总生存预后列线图的开发与验证

Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
PubMed 文献 · Eur J Cancer · 2019-07-03

该研究利用AURELIA试验化疗组和CARTAXHY试验全部患者数据开发了包含6个预处理特征的铂耐药卵巢癌总生存列线图,并在PENELOPE和AURELIA贝伐珠单抗-化疗组中独立验证。列线图区分度C-statistic在训练组为0.69,PENELOPE验证组为0.59,AURELIA贝伐珠单抗-化疗验证组为0.67,可用于临床试验分层和患者预后咨询。

要点

  • 列线图包含6个预后因素:体力状态、腹水、最大肿瘤大小、CA-125、无铂间期和原发铂耐药。
  • 训练组中好、中、差预后组中位OS分别为25.3、15.2和7.4个月。
  • 列线图可用于铂耐药卵巢癌临床试验患者分层及预后咨询。

核心结论

  • 基于6个预处理特征的列线图可预测铂耐药卵巢癌患者的总生存,并可用于临床试验分层和预后咨询。

研究设计与样本

  • 列线图开发使用AURELIA试验化疗组和CARTAXHY试验全部患者作为训练队列,基于预处理特征构建多变量比例风险模型。
  • 在PENELOPE队列和AURELIA贝伐珠单抗-化疗组中独立验证列线图的区分度和校准度。

主要发现

  • 列线图包含6个显著OS预测因子,按重要性依次为体力状态、腹水、最大肿瘤大小、CA-125、无铂间期和原发铂耐药,C-statistic为0.69。
  • 训练队列中好、中、差预后组中位OS分别为25.3、15.2和7.4个月。
  • PENELOPE验证队列(C-statistic 0.59)中好、中、差预后组中位OS分别为18.5、10.3和5.8个月。
  • AURELIA贝伐珠单抗-化疗验证队列(C-statistic 0.67)中好、中、差预后组中位OS分别为26.7、13.8和10.0个月。

临床怎么用

  • 该列线图可辅助肿瘤内科医生对铂耐药卵巢癌化疗患者进行预后分层和生存咨询。
  • 列线图可用于临床试验中按预后分组进行患者分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platinum-resistant ovarian cancer (PROC) is associated with a variable prognosis and unpredictable survival times. We have developed and validated a prognostic nomogram with the objective of improving the prediction of overall survival (OS) in patients treated with chemotherapy. METHODS: The nomogram was developed using data from a training cohort of patients from two trials, including the chemotherapy-only arm in AURELIA and all randomised patients in CARTAXHY. Multivariable proportional hazards models were generated based on pretreatment characteristics to develop a nomogram that classifies patients based on OS. We subsequently assessed the performance of the nomogram in terms of discrimination and calibration in independent validation patient cohorts: PENELOPE and the bevacizumab-chemotherapy arm of AURELIA. RESULTS: The nomogram included six significant OS predictors, in order of importance: performance status, ascites, size of the largest tumour, CA-125, platinum-free interval and primary platinum resistance (C-statistic 0.69). In the training cohort, the median OS in the good, intermediate and poor prognosis groups was 25.3, 15.2 and 7.4 months, respectively. In the PENELOPE validation cohort (C-statistic 0.59), the median OS in the good, intermediate and poor prognosis groups was 18.5, 10.3 and 5.8 months, respectively. In the AURELIA bevacizumab-chemotherapy validation cohort (C-statistic 0.67), the median OS in good, intermediate and poor prognosis groups was 26.7, 13.8 and 10.0 months, respectively. CONCLUSIONS: This nomogram with six pretreatment characteristics allows prediction of OS in PROC and could be used for stratification of patients in clinical trials as well as for counselling patients about prognosis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee CK, Asher R, Friedlander M, et al. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. Eur J Cancer. 2019. PMID: 31279306. doi:10.1016/j.ejca.2019.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。